94 related articles for article (PubMed ID: 12186410)
1. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
3. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects.
Kita T; Sakaeda T; Adachi S; Sakai T; Aoyama N; Hatanaka H; Kasuga M; Okumura K
Biol Pharm Bull; 2001 Oct; 24(10):1176-80. PubMed ID: 11642327
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
5. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Ma JJ; Liu CG; Li JH; Cao XM; Sun SL; Yao X
Clin Chim Acta; 2009 Sep; 407(1-2):30-5. PubMed ID: 19560446
[TBL] [Abstract][Full Text] [Related]
6. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.
Yokogawa K; Nakaharu T; Ishizaki J; Ozaki E; Takeda Y; Mabuchi H; Matsushita R; Kimura K; Nakashima E; Ichimura F; Miyamoto K
Int J Pharm; 2001 Oct; 229(1-2):183-91. PubMed ID: 11604271
[TBL] [Abstract][Full Text] [Related]
7. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
[TBL] [Abstract][Full Text] [Related]
8. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
[TBL] [Abstract][Full Text] [Related]
9. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism.
Okumura K; Kita T; Chikazawa S; Komada F; Iwakawa S; Tanigawara Y
Clin Pharmacol Ther; 1997 May; 61(5):509-17. PubMed ID: 9164413
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
11. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.
Ohtani T; Hiroi A; Sakurane M; Furukawa F
Br J Dermatol; 2003 May; 148(5):1035-9. PubMed ID: 12786839
[TBL] [Abstract][Full Text] [Related]
12. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
13. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Bates TR; Blumenthal HP; Pieniaszek HJ
Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
[TBL] [Abstract][Full Text] [Related]
14. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.
Cascorbi I; Brockmöller J; Mrozikiewicz PM; Bauer S; Loddenkemper R; Roots I
Cancer Res; 1996 Sep; 56(17):3961-6. PubMed ID: 8752164
[TBL] [Abstract][Full Text] [Related]
15. Urinary acetylated metabolites and N-acetyltransferase-2 genotype in human subjects treated with a para-phenylenediamine-containing oxidative hair dye.
Nohynek GJ; Skare JA; Meuling WJ; Hein DW; De Bie AT; Toutain H
Food Chem Toxicol; 2004 Nov; 42(11):1885-91. PubMed ID: 15350687
[TBL] [Abstract][Full Text] [Related]
16. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
[TBL] [Abstract][Full Text] [Related]
17. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?
Le Marchand L; Sivaraman L; Franke AA; Custer LJ; Wilkens LR; Lau AF; Cooney RV
Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):449-55. PubMed ID: 8781741
[TBL] [Abstract][Full Text] [Related]
18. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.
Bakayev VV; Mohammadi F; Bahadori M; Sheikholslami M; Javeri A; Masjedi MR; Velayati AA
Eur J Clin Pharmacol; 2004 Sep; 60(7):467-71. PubMed ID: 15316701
[TBL] [Abstract][Full Text] [Related]
19. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer.
Gil JP; Lechner MC
Carcinogenesis; 1998 Jan; 19(1):37-41. PubMed ID: 9472690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
